Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000036226 | SCV000059878 | uncertain significance | not specified | 2011-09-02 | criteria provided, single submitter | clinical testing | Variant classified as Uncertain Significance - Favor Benign. The Arg2070Gln vari ant in MYO7A has not been reported in the literature nor previously identified b y our laboratory. Computational analyses (biochemical amino acid properties, hom ology, PolyPhen2, SIFT, AlignGVGD) do not provide strong support for or against pathogenicity. In summary, the clinical significance of this variant cannot be d etermined at this time. |
Labcorp Genetics |
RCV001038973 | SCV001202478 | likely benign | not provided | 2024-03-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001038973 | SCV001813417 | uncertain significance | not provided | 2024-05-28 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV001831644 | SCV002088537 | uncertain significance | Usher syndrome type 1B | 2019-11-11 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004734548 | SCV005346596 | uncertain significance | MYO7A-related disorder | 2024-09-18 | no assertion criteria provided | clinical testing | The MYO7A c.6209G>A variant is predicted to result in the amino acid substitution p.Arg2070Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.025% of alleles in individuals of East Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |